Literature DB >> 16488379

Non-motor symptoms of Parkinson's disease: diagnosis and management.

K Ray Chaudhuri1, Daniel G Healy, Anthony H V Schapira.   

Abstract

The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics related to dopamine deficiency that are a consequence of degeneration of the substantia nigra pars compacta. However, non-dopaminergic and non-motor symptoms are sometimes present before diagnosis and almost inevitably emerge with disease progression. Indeed, non-motor symptoms dominate the clinical picture of advanced Parkinson's disease and contribute to severe disability, impaired quality of life, and shortened life expectancy. By contrast with the dopaminergic symptoms of the disease, for which treatment is available, non-motor symptoms are often poorly recognised and inadequately treated. However, attention is now being focused on the recognition and quantitation of non-motor symptoms, which will form the basis of improved treatments. Some non-motor symptoms, including depression, constipation, pain, genitourinary problems, and sleep disorders, can be improved with available treatments. Other non-motor symptoms can be more refractory and need the introduction of novel non-dopaminergic drugs. Inevitably, the development of treatments that can slow or prevent the progression of Parkinson's disease and its multicentric neurodegeneration provides the best hope of curing non-motor symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 16488379     DOI: 10.1016/S1474-4422(06)70373-8

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  660 in total

1.  Management of sexual dysfunction in Parkinson's disease.

Authors:  Gila Bronner; David B Vodušek
Journal:  Ther Adv Neurol Disord       Date:  2011-11       Impact factor: 6.570

2.  Cognition in non-demented Parkinson's disease vs essential tremor: A population-based study.

Authors:  Á Sánchez-Ferro; J Benito-León; E D Louis; I Contador; J Hernández-Gallego; V Puertas-Martín; F Bermejo-Pareja
Journal:  Acta Neurol Scand       Date:  2017-03-05       Impact factor: 3.209

3.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

Review 4.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

5.  Restless legs syndrome and Parkinson's disease in men.

Authors:  Xiang Gao; Michael A Schwarzschild; Eilis J O'Reilly; Hao Wang; Alberto Ascherio
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

6.  Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease.

Authors:  Hisayoshi Oka; Chizuko Toyoda; Makiko Yogo; Soichiro Mochio
Journal:  J Neurol       Date:  2010-01-30       Impact factor: 4.849

7.  Pharmacotherapy in Parkinson's disease: case studies.

Authors:  Tiago Mestre; Joaquim J Ferreira
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

Review 8.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

9.  Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire.

Authors:  David Crosiers; Barbara Pickut; Jessie Theuns; Peter Paul De Deyn; Christine Van Broeckhoven; Pablo Martinez-Martin; K Ray Chaudhuri; Patrick Cras
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

10.  Erectile function and risk of Parkinson's disease.

Authors:  Xiang Gao; Honglei Chen; Michael A Schwarzschild; Dale B Glasser; Giancarlo Logroscino; Eric B Rimm; Alberto Ascherio
Journal:  Am J Epidemiol       Date:  2007-09-17       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.